Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT00726687

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00726687. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1b study of Indibulin in combination with Capecitabine in advanced solid tumors.

Study identification

NCT ID: NCT00726687
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Alaunos Therapeutics; Industry
Enrollment: 7 participants

Conditions and interventions

Conditions

Advanced Solid Tumors

Interventions

indibulin Drug
capecitabine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 19, 2008 (Actual)
Primary completion: Sep 29, 2009 (Actual)
Completion: Sep 29, 2009 (Actual)
Last update posted: Sep 30, 2026

2008 – 2009

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Not listed	Indianapolis	Indiana	—	—
Not listed	Las Vegas	Nevada	—	—
Not listed	Vancouver	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00726687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2026 · Synced Nov 12, 2026